MagForce

About MagForce

MagForce AG is a pioneering company in the field of nanomedicine, specializing in the development and commercialization of innovative cancer treatments. The company operates primarily in the United States, Canada, Guam, Puerto Rico, and the US Virgin Islands. MagForce's core product is a patented therapy that uses nanotechnology to target and destroy cancerous cells with high precision, thereby minimizing damage to surrounding healthy tissue. This therapy is particularly effective for treating tumors and is designed to be both highly effective and gentle on patients.

MagForce serves a diverse range of clients, including hospitals, oncology centers, and individual patients seeking advanced cancer treatment options. The company operates in the healthcare and biotechnology markets, focusing on oncology.

MagForce's business model is based on the commercialization of its proprietary nanotechnology-based therapies. The company generates revenue through the sale of its treatment systems to medical institutions and through direct treatment services provided to patients. Additionally, MagForce engages in partnerships and collaborations with other healthcare providers and research institutions to expand its market reach and enhance its technological capabilities.